Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19397686 | 1.00 | MAOB (0.35) | MAOBALDH1A1TSHRMAPK1 | |
| SCHEMBL19397681 | 1.00 | MAOB (0.35) | MAOBALDH1A1TSHRMAPK1 | |
| SCHEMBL13995988 | 0.84 | MAOB (0.39) | MAOBALDH1A1TSHRMAPK1 | |
| SCHEMBL15267362 | 0.78 | MAOB (0.33) | MAOBTSHR | |
| SCHEMBL22276640 | 0.78 | MAOB (0.33) | MAOB | |
| SCHEMBL20217227 | 0.78 | MAOB (0.38) | MAOB | |
| SCHEMBL18821601 | 0.78 | — | — | |
| SCHEMBL20618251 | 0.78 | — | — | |
| SCHEMBL12059072 | 0.78 | MAOB (0.33) | MAOBTSHR | |
| SCHEMBL28230538 | 0.78 | TSHR (0.45) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021239058-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2021-12-02 | — | — | WO | disclosed |
| US-20160333006-A1 | ARYL LACTA KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-17 | — | — | US | disclosed |
| US-8901305-B2 | Aryl lactam kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| WO-2014022167-A1 | ARYL LACTAM KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-06 | — | — | WO | disclosed |
| US-7384952-B2 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-10 | — | — | US | disclosed |
| US-7384952-B2 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-10 | — | — | US | disclosed |
| EP-1857459-A2 | Pyrazolopyrimidine compound and a process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333006-A1 | ARYL LACTA KINASE INHIBITORS | AAK1, NCK1, ANKK1 | MAOB 2699/4885ALDH1A1 1939/4885TSHR 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.